product summary
Loading...
company name :
Bio-Rad
other brands :
Biogenesis, Serotec, AbD Serotec, Oxford Biotechnology
product type :
antibody
product name :
Mouse anti Influenza A Nucleoprotein
catalog :
MCA400
quantity :
1 mg
price :
721 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
AA5H
reactivity :
Alphainfluenzavirus
application :
western blot, immunocytochemistry
more info or order :
Bio-Rad product webpage
citations: 16
Published Application/Species/Sample/DilutionReference
  • immunocytochemistry; Alphainfluenzavirus; loading ...; fig 3a
Kühnl A, Musiol A, Heitzig N, Johnson D, Ehrhardt C, Grewal T, et al. Late Endosomal/Lysosomal Cholesterol Accumulation Is a Host Cell-Protective Mechanism Inhibiting Endosomal Escape of Influenza A Virus. MBio. 2018;9: pubmed publisher
  • immunocytochemistry; Alphainfluenzavirus; 1:1000; fig 1
Liedmann S, Hrincius E, Guy C, Anhlan D, Dierkes R, Carter R, et al. Viral suppressors of the RIG-I-mediated interferon response are pre-packaged in influenza virions. Nat Commun. 2014;5:5645 pubmed publisher
Lesch M, Luckner M, Meyer M, Weege F, Gravenstein I, Raftery M, et al. RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals. PLoS Pathog. 2019;15:e1007601 pubmed publisher
Kathum O, Schräder T, Anhlan D, Nordhoff C, Liedmann S, Pande A, et al. Phosphorylation of influenza A virus NS1 protein at threonine 49 suppresses its interferon antagonistic activity. Cell Microbiol. 2016;18:784-91 pubmed publisher
Delgado Ortega M, Melo S, Punyadarsaniya D, Rame C, Olivier M, Soubieux D, et al. Innate immune response to a H3N2 subtype swine influenza virus in newborn porcine trachea cells, alveolar macrophages, and precision-cut lung slices. Vet Res. 2014;45:42 pubmed publisher
Friesenhagen J, Viemann D, Börgeling Y, Schmolke M, Spiekermann C, Kirschnek S, et al. Highly pathogenic influenza viruses inhibit inflammatory response in monocytes via activation of rar-related orphan receptor ROR?. J Innate Immun. 2013;5:505-18 pubmed publisher
Zhai W, Zhang D, Mai C, Choy J, Jian G, Sra K, et al. Comparison of different cell substrates on the measurement of human influenza virus neutralizing antibodies. PLoS ONE. 2012;7:e52327 pubmed publisher
Friesenhagen J, Boergeling Y, Hrincius E, Ludwig S, Roth J, Viemann D. Highly pathogenic avian influenza viruses inhibit effective immune responses of human blood-derived macrophages. J Leukoc Biol. 2012;92:11-20 pubmed publisher
Demirov D, Gabriel G, Schneider C, Hohenberg H, Ludwig S. Interaction of influenza A virus matrix protein with RACK1 is required for virus release. Cell Microbiol. 2012;14:774-89 pubmed publisher
Hassan I, Zhang M, Powers L, Shao J, Baltrusaitis J, Rutkowski D, et al. Influenza A viral replication is blocked by inhibition of the inositol-requiring enzyme 1 (IRE1) stress pathway. J Biol Chem. 2012;287:4679-89 pubmed publisher
Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, et al. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 2012;13:207-18 pubmed publisher
Meier S, Bel M, L huillier A, Crisinel P, Combescure C, Kaiser L, et al. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine. 2011;29:3548-57 pubmed publisher
Gabay C, Bel M, Combescure C, Ribi C, Meier S, Posfay Barbe K, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum. 2011;63:1486-96 pubmed publisher
Kim M, Jeong O, Kang H, Paek M, Kwon J, Song C, et al. Pathogenicity and transmission studies of H7N7 avian influenza virus isolated from feces of magpie origin in chickens and magpie. Vet Microbiol. 2010;141:268-74 pubmed publisher
Jeong O, Kim M, Kim M, Kang H, Kim H, Kim Y, et al. Experimental infection of chickens, ducks and quails with the highly pathogenic H5N1 avian influenza virus. J Vet Sci. 2009;10:53-60 pubmed
Valdespino V, Gorodezky C, Ortiz V, Kaufmann A, Román Basaure E, Vazquez A, et al. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol. 2005;96:92-102 pubmed
product information
EntityType :
Monoclonal Antibody
EntityCategory :
Antibodies
ProductCode :
MCA400
Description :
Mouse anti Influenza A Nucleoprotein
Specificity :
Influenza A Nucleoprotein
TargetSpecies :
Viral
Host :
Mouse
Format :
Purified
Isotypes :
IgG2a
Applications :
WB,P,IF
ApplicationTypes :
Western Blotting,Immunohistology - Paraffin,Immunofluorescence
Clone :
AA5H
Quantity :
1 mg
QuantityValue :
1
QuantityType :
mg
EntityFormats :
Purified
UNSPSC :
41116161
Concentration :
IgG concentration 1.0 mg/ml
ProductForm :
Purified IgG - liquid
NotForSaleInCountries :
AU
PriceGBP :
503
PriceEUR :
703
PriceUSD :
721 USD
PriceCHF :
765
PriceSEK :
7838
PriceNOK :
8085
PriceDKK :
5244
more info or order :
Bio-Rad product webpage
company information
Bio-Rad
Endeavour House, Langford Business Park
Langford Lane, Kidlington
OXON, OX5 1GE
antibody_sales_uk@bio-rad.com
https://www.bio-rad-antibodies.com
1 800 265 7376 (North America)
44 (0)1865 852 700 (Rest of World)
headquarters: UK
Bio-Rad is one of the world's leading antibody manufacturers, offering over 12,000 antibodies and related reagents for a focused range of research areas such as immunology, cancer, veterinary research and cell biology through its antibody experts formerly known as AbD Serotec.
The range includes apoptosis kits, autophagy reagents, CD markers, epitope tag antibodies, immunology antibodies, neuroscience antibodies, and veterinary reagents.
Bio-Rad has an ISO 9001 and ISO 13485 certified production facility in the United Kingdom as well as ISO 9001 certified facilities in Germany and the United States.
Our expertise extends to traditional and recombinant antibody generation and production services. Our custom generation service delivers antibodies in as little as 8 weeks with greater than 90% success. The in vitro technology enables selection of antibodies to challenging targets, long term consistent supply, and provision of the antibody sequence.
At Bio-Rad we are committed to your success when using our antibodies and we focus on providing the technology, products and all the supporting information you need to excel in your research.